Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies

doi:10.1007/s11427-022-2215-6

	Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies
	Ling, Zhiyang 1,2; Yi, Chunyan 1,2; Sun, Xiaoyu 1,2; Yang, Zhuo 1,2; Sun, Bing1,2,3
	2022-11-01
发表期刊	SCIENCE CHINA-LIFE SCIENCES (IF:8.0[JCR-2023],7.3[5-Year])
ISSN	1674-7305
EISSN	1869-1889
发表状态	已发表
DOI	10.1007/s11427-022-2215-6
摘要	Antibody therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have been approved in many countries, with most being developed based on the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 has an exceptional ability to mutate under the pressure of host immunity, especially the immune-dominant spike protein of the virus, which is the target of both antibody drugs and vaccines. Given the continuous evolution of the virus and the identification of critical mutation sites, the World Health Organization (WHO) has named 5 variants of concern (VOCs): 4 are previously circulating VOCs, and 1 is currently circulating (Omicron). Due to multiple mutations in the spike protein, the recently emerged Omicron and descendent lineages have been shown to have the strongest ability to evade the neutralizing antibody (NAb) effects of current antibody drugs and vaccines. The development and characterization of broadly neutralizing antibodies (bNAbs) will provide broad strategies for the control of the sophisticated virus SARS-CoV-2. In this review, we describe how the virus evolves to escape NAbs and the potential neutralization mechanisms that associated with bNAbs. We also summarize progress in the development of bNAbs against SARS-CoV-2, human coronaviruses (CoVs) and other emerging pathogens and highlight their scientific and clinical significance.
关键词	antibody therapy broad neutralizing antibody human coronaviruses SARS-CoV-2
URL	查看原文
收录类别	SCI
语种	英语
资助项目	Ministry of Science and Technology of China[2018YFA0507402] ; Key International Partnership Program of the Chinese Academy of Sciences[153D31KYSB20180055] ; National Natural Science Foundation of China["32270991","32100123","32100751"]
WOS研究方向	Life Sciences & Biomedicine - Other Topics
WOS类目	Biology
WOS记录号	WOS:000889431700001
出版者	SCIENCE PRESS
引用统计	正在获取...
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/258936
专题	生命科学与技术学院_特聘教授组_孙兵组
通讯作者	Sun, Bing
作者单位	1.Chinese Acad Sci, Ctr Excellence Mol Cell Sci, Shanghai Inst Biochem & Cell Biol, State Key Lab Cell Biol, Shanghai 200031, Peoples R China 2.Univ Chinese Acad Sci, Beijing 100049, Peoples R China 3.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
通讯作者单位	生命科学与技术学院
推荐引用方式 GB/T 7714	Ling, Zhiyang,Yi, Chunyan,Sun, Xiaoyu,et al. Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies[J]. SCIENCE CHINA-LIFE SCIENCES,2022.
APA	Ling, Zhiyang,Yi, Chunyan,Sun, Xiaoyu,Yang, Zhuo,&Sun, Bing.(2022).Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies.SCIENCE CHINA-LIFE SCIENCES.
MLA	Ling, Zhiyang,et al."Broad strategies for neutralizing SARS-CoV-2 and other human coronaviruses with monoclonal antibodies".SCIENCE CHINA-LIFE SCIENCES (2022).